同和药业(300636) - 2017 Q3 - 季度财报

Financial Performance - Revenue for the reporting period reached ¥69,388,793.93, up 29.60% from the same period last year[8] - Net profit attributable to shareholders was ¥18,190,358.79, marking a significant increase of 125.01% year-over-year[8] - Basic earnings per share improved to ¥0.23, a rise of 76.92% compared to the previous year[8] - The total operating revenue for Q3 2017 reached CNY 69,388,793.93, an increase from CNY 53,539,039.18 in the previous period[41] - Net profit for the period was CNY 18,190,358.79, significantly higher than CNY 8,084,165.98 in the previous year, indicating a growth of approximately 125.9%[42] - The total profit for the current period was ¥60,120,549.12, an increase of 43.98% from ¥41,722,959.85 in the previous period[50] - The company reported a net increase in cash and cash equivalents of -CNY 11,738,694.75, contrasting with an increase of CNY 83,097.24 in the previous period[58] Assets and Liabilities - Total assets increased to ¥699,195,007.06, a growth of 66.89% compared to the previous year[8] - Net assets attributable to shareholders rose to ¥619,955,908.80, reflecting a 103.49% increase year-over-year[8] - The total liabilities decreased to CNY 79,239,098.26 from CNY 114,305,474.11, showing a reduction of approximately 30.7%[35] - The company's equity increased to CNY 619,955,908.80, up from CNY 304,655,079.34, indicating a growth of about 103.5%[35] - The company's current assets totaled CNY 448,556,522.21, up from CNY 213,532,005.34 at the beginning of the year, indicating a significant increase in liquidity[33] Cash Flow - Cash flow from operating activities showed a decline of 24.32%, totaling ¥24,199,925.39 year-to-date[8] - Net cash flow from operating activities decreased by 24.32% to ¥24,199,925.39, primarily due to increased raw material procurement and taxes[22] - Investment activities generated a net cash outflow of ¥291,172,329.96, a 1,212.99% increase compared to the previous year, due to increased capital expenditures[22] - Net cash flow from financing activities surged by 2,582.03% to ¥256,935,850.66, driven by IPO fundraising of ¥268.2 million[22] - Financing cash inflow reached CNY 325,850,272.85, compared to CNY 43,588,660.10 in the previous period, marking an increase of about 645.5%[60] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,310[12] - The top shareholder, Pang Zhengwei, holds an 18.55% stake, with 15,081,081 shares pledged[12] - The number of restricted stock options granted was adjusted to 1,548,000 shares, with 1,298,000 shares granted initially to 82 individuals[27] Other Financial Metrics - The weighted average return on equity decreased to 2.98%, down 4.98% from the previous year[8] - Government subsidies recognized in the current period amounted to ¥8,287,424.06[9] - The company reported an investment income of CNY 788,434.24 during the period, contributing positively to overall profitability[42] - The company recorded other income of ¥1,224,225.06, which was not reported in the previous period[50]